To mitigate increased estrogen concentration during the ovulation stimulation cycle, it is recommended to add aromatase inhibitors like letrozole at the beginning of the stimulation cycle in estrogen sensitive cancers such as breast cancer and endometrial adenocarcinoma [2, 3, 8]. This evidence concerns the gene CYP19A1 and breast cancer.